vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
Valens Semiconductor Ltd. is the larger business by last-quarter revenue ($17.3M vs $10.7M, roughly 1.6× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -42.2%, a 65.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 8.1%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
ABUS vs VLN — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $17.3M |
| Net Profit | $2.5M | $-7.3M |
| Gross Margin | — | 63.0% |
| Operating Margin | 13.9% | -46.4% |
| Net Margin | 23.5% | -42.2% |
| Revenue YoY | 522.2% | 8.1% |
| Net Profit YoY | 112.7% | 29.3% |
| EPS (diluted) | $0.01 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $17.3M | ||
| Q2 25 | $10.7M | $17.1M | ||
| Q1 25 | — | $16.8M | ||
| Q3 24 | — | $16.0M | ||
| Q2 24 | — | $13.6M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — | ||
| Q2 23 | $4.7M | $24.2M |
| Q3 25 | — | $-7.3M | ||
| Q2 25 | $2.5M | $-7.2M | ||
| Q1 25 | — | $-8.3M | ||
| Q3 24 | — | $-10.4M | ||
| Q2 24 | — | $-8.9M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — | ||
| Q2 23 | $-17.1M | $-4.6M |
| Q3 25 | — | 63.0% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.9% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 61.4% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 61.8% |
| Q3 25 | — | -46.4% | ||
| Q2 25 | 13.9% | -43.3% | ||
| Q1 25 | — | -56.2% | ||
| Q3 24 | — | -76.3% | ||
| Q2 24 | — | -69.2% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | -21.4% |
| Q3 25 | — | -42.2% | ||
| Q2 25 | 23.5% | -42.1% | ||
| Q1 25 | — | -49.4% | ||
| Q3 24 | — | -64.6% | ||
| Q2 24 | — | -65.2% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | -19.0% |
| Q3 25 | — | $-0.07 | ||
| Q2 25 | $0.01 | $-0.07 | ||
| Q1 25 | — | $-0.08 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.08 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $93.5M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $108.8M |
| Total Assets | $103.3M | $136.7M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $93.5M | ||
| Q2 25 | $37.4M | $102.7M | ||
| Q1 25 | — | $112.5M | ||
| Q3 24 | — | $133.1M | ||
| Q2 24 | — | $105.9M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | $138.0M |
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — |
| Q3 25 | — | $108.8M | ||
| Q2 25 | $83.0M | $116.5M | ||
| Q1 25 | — | $128.6M | ||
| Q3 24 | — | $147.0M | ||
| Q2 24 | — | $153.5M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — | ||
| Q2 23 | $134.7M | $166.3M |
| Q3 25 | — | $136.7M | ||
| Q2 25 | $103.3M | $144.8M | ||
| Q1 25 | — | $154.6M | ||
| Q3 24 | — | $171.9M | ||
| Q2 24 | — | $175.8M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — | ||
| Q2 23 | $176.8M | $184.3M |
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-4.7M |
| Free Cash FlowOCF − Capex | — | $-4.9M |
| FCF MarginFCF / Revenue | — | -28.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-4.7M | ||
| Q2 25 | $-15.7M | $-211.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | — | $-225.0K | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-19.6M | $358.0K |
| Q3 25 | — | $-4.9M | ||
| Q2 25 | — | $-330.0K | ||
| Q1 25 | — | $-8.0M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $-460.0K | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | $-419.0K |
| Q3 25 | — | -28.5% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | — | -47.3% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | -3.4% | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | -1.7% |
| Q3 25 | — | 1.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | — | 2.1% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 1.7% | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | 3.2% |
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
